Weekly Research Analysts’ Ratings Updates for Stemline Therapeutics (STML)

Several analysts have recently updated their ratings and price targets for Stemline Therapeutics (NASDAQ: STML):

  • 2/9/2018 – Stemline Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. “
  • 2/2/2018 – Stemline Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
  • 2/2/2018 – Stemline Therapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 1/26/2018 – Stemline Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 1/19/2018 – Stemline Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 1/10/2018 – Stemline Therapeutics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 1/5/2018 – Stemline Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. “
  • 1/4/2018 – Stemline Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 12/31/2017 – Stemline Therapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 12/29/2017 – Stemline Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 12/22/2017 – Stemline Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

Stemline Therapeutics Inc (NASDAQ:STML) traded up $0.20 during midday trading on Tuesday, hitting $15.55. 151,929 shares of the stock were exchanged, compared to its average volume of 344,001. Stemline Therapeutics Inc has a one year low of $6.35 and a one year high of $17.40. The firm has a market cap of $450.51, a P/E ratio of -6.05 and a beta of -0.02.

In other news, insider David Gionco sold 4,250 shares of the company’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $13.43, for a total transaction of $57,077.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Kenneth Hoberman sold 14,040 shares of the company’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $13.93, for a total transaction of $195,577.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 42,216 shares of company stock valued at $591,925. Corporate insiders own 15.70% of the company’s stock.

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Receive News & Ratings for Stemline Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply